Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments

David Cheerie(SickKids Foundation), Marlen C. Lauffer(Leiden University Medical Center), Ana Lisa Taylor Tavares(University of Leeds), Anne Gregor(University of Bern), Logan Newton(University of Toronto), Matthis Synofzik(German Center for Neurodegenerative Diseases), Annemieke Aartsma‐Rus(Leiden University Medical Center), Maya Chopra(Boston Children's Hospital), Hormos Salimi Dafsari(University of Cologne), Andrew C. Giles(University of British Columbia), Mina Ryten(Guy's Hospital), Jan Verheijen(ARUP Laboratories (United States)), Nour Elkhateeb(Cambridge University Hospitals NHS Foundation Trust), Kylie Montgomery(New England Biolabs (United States)), J. Morgan(Leiden University Medical Center), Alice E. Davidson(Moorfields Eye Hospital NHS Foundation Trust), Stephan Sanders(University of California, San Francisco), Gregory Costain(University of Toronto), Gabriele Siegel(University of Zurich), Timothy W. Yu(Boston Children's Hospital), Danique Beijer(German Center for Neurodegenerative Diseases), Laura V. Croft(Queensland University of Technology), Aubrie Soucy(Institut thématique Génétique, génomique et bioinformatique), Jennifer Friedman(Rady Children's Hospital-San Diego), Emily J. Blake(Massachusetts Institute of Technology), Bianca Zardetto(Leiden University Medical Center), Bushra Haque(SickKids Foundation), Emma Sherrill(Boston Children's Hospital), Anna Verwillow(Massachusetts General Hospital), Margaret Meserve(Boston Children's Hospital), Emil Schober(Max Planck Institute for Biology of Ageing), Patricia Sullivan, Stefanie Leonard(Somerville Hospital), Aastha Gandhi(University of Toronto), Rosan Lechner(Erasmus MC), Sean Williams(University of Toronto), Charu Kaiwar(Mayo Clinic)
medRxiv
September 28, 2024
Cited by 5


Related Papers